PLACEBO-CONTROLLED

作品数：122被引量：659H指数：15
导出分析报告
相关领域：医药卫生农业科学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划国家科技支撑计划中国博士后科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 基金=World Health Organizationx
共 条 记 录，以下是1-1
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Interim results from ongoing PhaseⅢ placebo-controlled,randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication被引量：1
《Hepatoma Research》2020年第1期11-18,共8页Aldar S.Bourinbaiar Jigjidsuren Chinburen Purev Batchuluun Chogsom Munkhzaya DandiiOyungerel Dorjiin Dandii Galyna A.Kutsyna Hulan Tsogkhuu Marina G.Tarakanovskaya Alan A.Reid Vika Borisova Allen I.Bain Vichai Jirathitikal 
This study would never have had a chance to succeed if we did not receive the financial contribution from our former patient with terminal HCC,Dr.Steve Kramer-now in complete remission since 2014-and his spouse Jane Kramer,who as our genuine friends generously supported our effort over many years.Additional support was provided by several other patients who contributed extra in addition to regular payment for Hepko-V5.They were not involved in clinical study design,collection,analysis and interpretation of data.
Aim:We aimed to further investigate the role of hepcortespenlisimut-L(Hepko-V5 or V5),a new oral immunotherapy developed by us,for hepatocellular carcinoma(HCC)indication.Methods:The interim data from ongoing PhaseⅢp...
关键词：Hepatocellular carcinoma ALPHA-FETOPROTEIN alanine transaminase aspartate transaminase IL-2 INF-Γ TNF-α CD69 Ki67 CD4 CD8 T lymphocytes 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部